MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of transscleral laser treatment using MicroPulse® technology (MicroPulse TLT) can safely and effectively furthe ...

Industry Overview - Glaucoma is the leading cause of irreversible blindness globally, highlighting the critical need for effective treatment options [1] - The market for Minimally Invasive Glaucoma Surgery (MIGS) is expected to return to growth by 2026, despite current challenges [2] Market Dynamics - There has been significant progress in MIGS, improving clinical outcomes for patients with glaucoma [1] - The industry is currently facing headwinds due to changes in Local Coverage Determinations (LCDs), but these challenges are anticipated to ease by Q4 [1]